To wait, or too late? modeling the effects of delayed Ofatumumab treatment in relapsing-remitting Multiple Sclerosis.
Stephen Maxwell MontgomeryLuke GreenHajer KarouiRichard St John NicholasJaclyn LohPublished in: Journal of medical economics (2022)
The DES model provided a means by which the magnitude of benefit associated with earlier ofatumumab initiation could be quantified; fewer relapses and a prolonged time to wheelchair were predicted.